This pentasacharide anticoagulant (Arixtra) does not cross react with HIT antibodies. Early experience with its use in HIT patients is favorable. It’s not approved for such use at present, and not recommended in guidelines. I predict it will eventually emerge as a treatment for HIT. The topic is reviewed here. (Pharmacotherapy, via Medscape).
See update here!